Cardiff Oncology, Inc. 8-K

What Happened
Cardiff Oncology announced it filed a lawsuit on May 19, 2026 in the U.S. District Court for the Southern District of California against Nerviano Medical Sciences S.r.l. (NMS). The suit challenges NMS’s allegation that Cardiff materially breached the March 13, 2017 License Agreement by not naming NMS employee Dr. Barbara Valsasina as a joint inventor on U.S. Pat. Nos. 12,144,813 and 12,263,173 (the “Cardiff Patents”). On May 27, 2026 NMS sent a written notice purporting to terminate the Agreement under Section 11.3, alleging breaches including inventorship issues (Section 10.2(c)) and failure to use “Commercially Reasonable Efforts” for development and regulatory approvals for onvansertib (Sections 7.3, 7.5, 7.9). Cardiff says the termination notice is legally ineffective, factually unsupported and procedurally improper, and has said it will continue to perform under the Agreement while seeking injunctive relief and a declaratory judgment.

Key Details

• Lawsuit filed: May 19, 2026 in U.S. District Court, Southern District of California.
• NMS termination notice dated/received: May 27, 2026, citing alleged inventorship and failures re: onvansertib development and regulatory efforts.
• Patents at issue: U.S. Pat. Nos. 12,144,813 and 12,263,173; NMS employee named: Dr. Barbara Valsasina.
• Relief sought by Cardiff: injunctive relief to require NMS to continue performance under the Agreement and a declaratory judgment that Cardiff did not breach.

Why It Matters
This is a material legal dispute over rights and obligations under Cardiff’s 2017 license agreement that directly involves onvansertib development and related patent inventorship. For investors, the outcome could affect Cardiff’s ability to rely on the license, its control of the patents cited, and progress toward regulatory approvals or commercialization tied to the agreement. The company has not disclosed financial impacts in this filing; the matter is now in litigation and creates legal and operational uncertainty until resolved.